Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $-0.84. Vir Biotechnology bulls will hope ...

Vir Biotechnology, Inc.’s VIR share price has dipped by 5.45%, which has investors questioning if this is right time to buy.

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

SAN FRANCISCO, May 12, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago.

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Vir ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the ...

Tobevibart was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg ...

Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 ...